Recently the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene with transforming activity was identified in non-small cell lung cancer (NSCLC). In addition, NSCLC patients with the EML4-ALK fusion gene had a dramatic response and longer progression free survival after ALK inhibitor treatment than those without this fusion gene. However, the incidence and clinical and molecular characteristics of the EML4-ALK fusion gene in NSCLC patients of Taiwan are still unclear.
L ung cancer is the leading cause of cancer death worldwide. (1) Although there has been great improvement in the detection and treatment of lung cancer in the past 10 years, the overall 5-year survival rate remains low (15%). (1, 2) The great success of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), gefitinib and erlotinib, for treatment of lung adenocarcinoma has made targeted therapy an important therapeutic modality for major human cancers. (3, 4) Since the therapeutic responsiveness of EGFR-TKI is strongly associated with the presence of somatic EGFR mutations, genetic analyses of various molecular markers in tumor tissue have become standard laboratory tests for the clinical management of lung cancers. (5, 6) In 2007, Soda et al identified the fusion oncogene joining the echinoderm microtubule-associated protein-like-4 (EML4) and the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC). (7) They also demonstrated the transforming ability of this fusion gene. ALK is a 200 kDa receptor tyrosine kinase of the insulin receptor superfamily. Their signal pathway involves cell proliferation, differentiation, and anti-apoptosis. (7, 8) ALK translocation was first identified in anaplastic large cell lymphoma as nucleophosmin-ALK fusion protein resulting from chromosome rearrangement t(2;5)(p23;q35). (9) Various combinations of ALK with other proteins have subsequently been discovered. Almost all of the chimeric ALK genes are derived from genomic breakpoints between exons 19 and 20, leading the fusion of the 3'-end intracytoplasmic domain of ALK with the 5'-end dimerization domains from different partner proteins. (10, 11) In vitro oncogenic experiments and in vivo mouse models have confirmed the oncogenic potential of ALK fusion genes. (10, 11) Although ALK overexpression, point mutations and fusion proteins have been found associated with various neoplasms such as neuroblastoma, diffuse large B cell lymphoma, inflammatory myofibroblastic tumor, squamous cell carcinoma of the esophagus, and renal cell carcinoma, (12) the EML4-ALK fusion gene is unique to NSCLC. (13) In addition, multiple EML4-ALK variants in NSCLCs have been identified, and all of them could confer gain-of-function properties. (13) Recently, the United States Food and Drug Administration (FDA) conditionally approved crizotinib (an ALK inhibitor) for treatment of NSCLC, after its efficacy and safety profile were confirmed in NSCLC patients with ALK translocations in Phase I and Phase II trials. (14) (15) (16) Thus, detection of the EML4-ALK fusion gene has become a an important new molecular marker for NSCLC patients.
An understanding of the epidemiology and the prevalence is necessary before developing a surveillance strategy in a defined population for a particular disease. Although several published reports have demonstrated that the incidence of the EML4-ALK fusion gene in NSCLC is usually low (1.5% to 6.7%), and more commonly found in adenocarcinoma and non-smokers, (7, 13, (17) (18) (19) (20) reports on the clinical and molecular characteristics of the EML4-ALK fusion gene in NSCLC patients in Taiwan are still quite rare. (21) In this report, we detected the EML4-ALK fusion gene by reverse transcription-polymerase chain reaction (RT-PCR) in 64 NSCLC patients who had surgery at Chang Gung Memorial Hospital and correlated with ALK expression by immunohistochemical (IHC) study.
METHODS

Patients and tissues
Sixty-four fresh frozen tumor specimens from NSCLC patients receiving surgical resections at Chang Gung Memorial Hospital from May 2002 to April 2003 were obtained from the tissue bank of Chang Gung Memorial Hospital for RNA extraction and EML4-ALK fusion gene analyses. Signed informed consents were obtained. Paraffin sections of lung tumors from all of these patients were available for ALK protein expression analyses by IHC stain. The study protocol was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital.
RNA extraction and complementary DNA synthesis
Frozen lung cancer tissues of the 64 patients were used as starting materials for total RNA extraction by the Trizol method (Invitrogen, Carlsbad, CA, U.S.A.). Gel electrophoresis was performed to verify RNA quality. The resulting RNA was stored at -80°C until complementary DNA was synthesized with the SuperScript First-Strand synthesis system (Invitrogen).
Reverse transcription-polymerase chain reaction for detection of different EML4-ALK variants
Based on published nucleotide sequences and reports, (7, 19) different primers were employed in the present study to identify different EML4-ALK variants. Briefly, the primer set of Fusion-RT-S (5'-GTGCAGTGTTTAGCATTCTTGGGG-3') and Fusion-RT-AS (5'-TCTTGCCAGCAAAGCAG-TAGTTGG-3') was able to identify different variants by different base pairs (bp): variant 1 (247 bp), variant 4 (361 bp), variant 6 (316 bp) and variant 7 (385 bp). Variant 2 with 155 bp was identified by the primer set of Fusion 2-Genome-S (5'-AGCTACAT-CACACACCTTG ACTGG-3') and Fusion-Genome-AS (5'-AGCTTGCTCAGCTTGTACTCAGGG-3'). The primers E6A20-S (5'-TTCGAGCAT-CACCTTCTCC-3') and E6A20-AS (5'-GGACAC-CTGGCCTTCATAC-3') were used to detect variant 3 (3a: 482bp; 3b: 515 bp). For variant 5, V5b-S (5'-GATATGGAGATCCAGGGAGGC-3') and Fusion-RT-AS were used and the resultant product was 231 bp. The condition of the thermal cycle in the polymerase chain reaction (PCR) was the same as in previous reports, (19) If any PCR product with the expected size was obtained, nucleotide sequencing (Applied Biosystems PRISMR 3730 DNA Analyzer Sequencer Foster City, CA, U.S.A.) was performed. The resulting nucleotide sequences were verified by the Basic Local Alignment Search Tool (BLAST) program at National Center for Biotechnology Information to search for similar sequences.
ALK protein expression analyses by IHC study
An IHC stain using anti-ALK antibody (Invitrogen, Life Tech Corp) as the primary antibody was performed on the paraffin sections (5 µm thick) of the 64 NSCLC patients. The detection used the Ventana Discovery XT staining system with the ultraView Universal DAB detection kit (Ventana Medical Systems, Inc, Tucson, AZ, U.S.A.). Deparaffinization was followed by 95 antigen retrieval in commercial tris-base buffer with boric acid and ethylene-diamine-tetraacetic acid (Cell Conditioning 1, Roche, Rotkreuz, Switzerland) for 30 minutes. Then the slides were incubated with primary antibody (1:500) at room temperature overnight, followed by washing and detection according to the manufacturer's protocol. The IHC stains were evaluated by two pathologists (TD Chen and SF Huang) without knowing the results of the EML4-ALK fusion gene study. The IHC stains for ALK, when positive, always stained diffusely. Thus, the ALK stains were graded according to the intensity only. Tumors with weak staining were graded as (1+); tumors with moderate staining were graded as (2+); those with strong staining were grade as (3+), similar to previous studies. (22, 23) EGFR and KRAS mutation analyses
The EGFR mutation analyses were performed by direct sequencing of the four coding sequences from exon 18 to 21. Kirsten ras oncogene (KRAS) mutation analyses were performed by direct sequencing of exons 2 and 3. The methodologies of the above 2 studies have been reported previously, (24, 25) The data of the EGFR and KRAS mutations in the 64 NSCLC patients have been included in our previously published reports. (24, 25) 
Statistical analysis
To analyze the differences in the major clinicopathological features correlated with ALK expression or the EML4-ALK fusion gene, the frequencies and proportions were compared by the conventional chi-square association test or Fisher's exact test (when there was at least a cell frequency less than 5). A two-sided p value less than 0.05 was considered statistically significant.
RESULTS
EML4-ALK fusion gene, and EGFR and KRAS mutations among the 64 NSCLC patients
Among the 64 NSCLC patients, there were 36 cases of adenocarcinoma, 23 of squamous cell carcinoma, 4 of adenosquamous carcinoma and one of large cell carcinoma. There were 3 tumors (4.69%) with the EML4-ALK fusion gene. Two were adenocarcinoma with variant 3 (including both variants 3a and 3b, with 3b predominant). One was adenosquamous carcinoma with variant 1 (Fig. 1) . EGFR mutations were found in 20 patients, all with adenocarcinoma except for one with adenosquamous carcinoma. Eight (40%) had L858R mutations and six (30%) had exon 19 deletions. KRAS mutation was found in 2 patients, both with adenocarcinoma. None of these three types of mutations coexisted. After exclusion of patients with squamous cell carcinoma or EGFR mutation (+), the incidence of the EML4-ALK fusion gene was 14.3% (3/21) in patients with EGFR wild type non-squamous cell carcinoma. The age, gender, smoking history, histology type, and tumor stage all had no significant associations with the EML4-ALK fusion gene. The clinical and molecular characteristics associated with EML4-ALK translocation are summarized in the Table. ALK protein expression by IHC study Among the 64 tumors, 9 tumors were totally negative for ALK expression, and 46 tumors were weakly positive (1+). Seven tumors were 2+, and only 2 tumors were strongly positive (3+) (Fig. 2B  and 2C ). All tumors with negative or weak staining for ALK (55/64, 85.9%) had no EML4-ALK translocation. In contrast, both tumors strongly positive for ALK were shown to harbor variant 3a+3b transcripts of the EML4-ALK fusion gene. One of the seven tumors with moderate positive staining (2+) had the EML4-ALK fusion gene (variant 1). Thus, strong ALK IHC staining was the only variable that was significantly associated with the EML4-ALK fusion gene (p = 0.0002). If we take IHC 2+ as a cut-off value for positive ALK expression, the overall sensitivity and specificity of ALK IHC for detection of the EML4-ALK fusion gene were 100% and 90.2%. The positive and negative predictive values in unselected NSCLC patients were 33.3% and 100%, respectively. After excluding 22 cases with EGFR or KRAS mutations, the sensitivity and specificity of ALK IHC for detection of the EML4-ALK fusion gene were 100% and 94.9%. The positive predictive value increased to 60%. 
DISCUSSION
In this study, the EML4-ALK fusion gene was found in 3 of the 64 NSCLCs (4.7%) and in 14.3% of 21 EGFR wild type non-squamous cell carcinoma. Both incidences were similar to previously published series, (7, 13, (17) (18) (19) (20) even though our case number was not large. The clinical and molecular characteristics shown in the Table also demonstrated features similar to those in previous reports in that none of the squamous cell carcinoma had the EML4-ALK fusion gene and there were more non-smokers than smokers. All patients with the EML4-ALK fusion gene had no co-existing EGFR or KRAS mutations. Although EML4-ALK fusion gene variants 1 and 2 have been the main variants reported in the literature, two variant 3 and only one variant 1 were found in our series, similar to the reports by Koivunen et al. (17) and Wong et al. from Hong Kong. (19) They also found variant 3 to be the most common type in their patient group. Our incidence of the EML4-ALK fusion gene in NSCLCs (4.7%) was also quite similar to Wong, et al (4.9%). Wu et al. from Taiwan reported a very high incidence (34%) of the EML4-ALK fusion gene in adenocarcinoma patients with wild type EGFR. (21) The above study only included adenocarcinoma patients with pleural effusions. Since their patients were a selected group, the data could not be compared with other published studies or the current report. One additional interesting finding in this study was that both patients with variant 3 had mixed 3a+3b with 3b being predominant. We double checked this result. Currently, only 4 reports have mentioned variant 3a and 3b of the EML4-ALK fusion gene. (13, 17, 18, 21) Among these, two papers mentioned the presence of variant 3 with mixed 3a+3b. (13, 17) In the report by Koivunen et al, (17) four of the 8 tumors with EML4-ALK translocation were variant 3, two were variant 1 and two were variant 4. All of their 4 tumors with variant 3 were mixed 3a+3b with 3b being predominant, similar to our results.
In this study, the two tumors with strong ALK staining (3+) both had the EML4-ALK fusion gene (variant 3a+3b). One of the seven tumors with moderate staining (2+) had the EML4-ALK fusion gene (variant 1). When compared with other clinical and molecular characteristics, ALK expression by IHC stain was the only variable that was significantly associated with the EML4-ALK fusion gene (p = 0.0002). If we use 2+ as a cut-off value for positive ALK expression by IHC stain, the overall sensitivity and specificity of the ALK IHC for EML4-ALK fusion gene were 100% and 90.2%. The above results suggest that ALK expression by IHC stain could be a good alternative screening method for detection of the EML4-ALK fusion gene when selecting NSCLC patients for ALK inhibitor treatment. This is an important issue, since RT-PCR for determination of the EML4-ALK fusion gene requires fresh tumor tissue for RNA extraction, which is often unavailable. Currently, break-apart fluorescence in situ hybridization (FISH) is the only conjunction test approved by the United States FDA to detect ALKrearranged NSCLC. FISH assay is also the only validated test able to predict the response to crizotinib. (26) However a reliable FISH assay requires technical expertise, and costs much more than an IHC stain. Detection of the EML4-ALK fusion gene by IHC stains could be a much easier and cheaper screening method for the EML4-ALK fusion gene in NSCLCs than break-apart FISH assay. Although a few published studies have demonstrated a good correlation between the ALK IHC method and FISH assay, (22, 23, 27, 28) 3 of these 4 reports did not have data on the EML4-ALK fusion gene for direct comparison with the ALK IHC or FISH results, since they were unable to get tumor RNA samples. It is worth mentioning that in the only published report which directly compared the diagnostic accuracy among RT-PCR, FISH, and ALK IHC methods, only 60% of the cases were interpretable using FISH assay. (28) Although FISH assay has been approved as the standard method for predicting ALK inhibitor response, a fundamental bias may stem from the low recovery rate of FISH assay on formalin-fixed paraffin embedded tissue. Correlation of IHC stain results with identification of the EML4-ALK fusion gene by RT-PCR and FISH assay in a larger number of NSCLC patients is warranted to draw a more confirmative conclusion. This will help to find the most costeffective method for determination of anti-ALK inhibitors usage in NSCLC patients in Taiwan.
